JAK1 and infection: Inhibition of JAK1 impairs cytokine production, which may result in reduced control of silent infections and increased risk of reactivation of latent infections (Heine et al., 2013b) In particular, ruxolitinib drastically reduces the quantity of natural killer (NK) cells (Schönberg et al., 2015).